- Home
- HE vs BEAM Comparison
HE vs BEAM Comparison
Compare HE & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HE
- BEAM
- Stock Information
- Founded
- HE 1891
- BEAM 2017
- Country
- HE United States
- BEAM United States
- Employees
- HE N/A
- BEAM N/A
- Industry
- HE Electric Utilities: Central
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HE Utilities
- BEAM Health Care
- Exchange
- HE Nasdaq
- BEAM Nasdaq
- Market Cap
- HE 1.9B
- BEAM 1.6B
- IPO Year
- HE N/A
- BEAM 2020
- Fundamental
- Price
- HE $11.06
- BEAM $17.59
- Analyst Decision
- HE Hold
- BEAM Strong Buy
- Analyst Count
- HE 4
- BEAM 11
- Target Price
- HE $11.19
- BEAM $48.90
- AVG Volume (30 Days)
- HE 1.6M
- BEAM 1.9M
- Earning Date
- HE 08-08-2025
- BEAM 08-05-2025
- Dividend Yield
- HE N/A
- BEAM N/A
- EPS Growth
- HE N/A
- BEAM N/A
- EPS
- HE N/A
- BEAM N/A
- Revenue
- HE $3,171,906,000.00
- BEAM $63,578,000.00
- Revenue This Year
- HE $23.08
- BEAM N/A
- Revenue Next Year
- HE $1.74
- BEAM $8.82
- P/E Ratio
- HE N/A
- BEAM N/A
- Revenue Growth
- HE 0.66
- BEAM N/A
- 52 Week Low
- HE $7.61
- BEAM $13.53
- 52 Week High
- HE $18.19
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- HE 49.80
- BEAM 45.97
- Support Level
- HE $10.38
- BEAM $16.49
- Resistance Level
- HE $10.83
- BEAM $17.73
- Average True Range (ATR)
- HE 0.24
- BEAM 0.87
- MACD
- HE 0.01
- BEAM 0.02
- Stochastic Oscillator
- HE 40.12
- BEAM 29.91
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.